摘要
目的探讨抗幽门螺杆菌感染治疗对急性冠脉综合征(ACS)患者的近期临床疗效。方法将120例有幽门螺杆菌感染(HP)的ACS患者随机分为治疗组和对照组,2组均给予ACS的常规治疗,治疗组再予奥美拉唑(奥克)20mg、克拉霉素(安吉尔宁)500mg、甲硝唑400mg,2次/d,连服1周。观察治疗前后2组临床疗效,同步观察血C-反应蛋白(CRP)、纤维蛋白原(FIB)、补体及血脂的变化。结果治疗组临床疗效与对照组比较差异有统计学意义(P<0.05);治疗后治疗组患者的CRP、C3、FIB的水平低于对照组(分别为P<0.01、P<0.05、P<0.01)。结论抗幽门螺杆菌感染治疗对ACS患者有较好的临床疗效,其机制可能与该类药物能显著降低炎症标记物CRP及FIB的水平有关。
Objective To investigate the recent clinical efficacy of anti-Helicobacter Pylori（HP） infection in treatment of patients with acute coronary syndrome （ACS）. Methods 120 ACS patients with HP infection were randomly divided into two groups, Both groups were administered with routine therapy, The trial group was additionally administered with drug of 20 mg of Omeprazole ,500 mg of Clarithromycin and 400 mg of Metronidazole again, twice a day, continue a week, Clinical efficacy and changes of CRP,FIB,complement and serum lipids in two groups were observed before and after treatment. Results There was statistics difference in clinical efficacy between the two groups（ P 〈 0. 05）. The level of CRP, C3 and FIB in the trial group were more lower than that in the control after treatment （ P 〈 0. 01, P 〈0. 05, P 〈 0. 01 ）. Conclusions Ant-HP infection has much curative effect in the treatment of ACS patients, The possible pathogenesis is that the drugs can reduce remarkably the level of C- reactive protein（CRP） and fibrinogen（FIB）.
出处
《实用全科医学》
2007年第10期891-892,共2页
Applied Journal Of General Practice
关键词
幽门螺杆菌
急性冠脉综合征
疗效评价
Helicobacter Pylori
Acute Coronary Syndrome
Efficacy evaluation
